Is Strata Critical Medical, Inc. (SRTAW) overvalued? · rev $248.7M
Strata Critical Medical, Inc. (SRTAW) common stock listed on NASDAQ.
This page asks whether Strata Critical Medical, Inc. (SRTAW) looks expensive on cached numbers — not a short thesis.
Latest reported SRTAW revenue for 2024-12-31 was $248.7M. Net income was -$27.3M. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. SRTAW currently screens at market cap $0.
SRTAW currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SRTAW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SRTAW stock page for the full model, not this heading.
Not investment advice.